Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. White Space Analysis
5.2. Porter’s Analysis
5.3. Pipeline Analysis (Phase III)
5.4. Peptide Drug Chemical Structure Trend Analysis
5.5. Separation Media for Peptide Drug Manufacturing
5.6. Covid-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017–2031
6.3.1. Cancer
6.3.2. Metabolic
6.3.3. CVD
6.3.4. Respiratory
6.3.5. GIT
6.3.6. Anti-infective
6.3.7. Dermatology
6.3.8. CNS
6.3.9. Renal
6.4. Market Attractiveness Analysis, by Application

7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Parenteral
7.3.2. Oral
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast, by Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Type, 2017–2031
8.3.1. Innovative
8.3.2. Generic
8.4. Market Attractiveness Analysis, by Type

9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Technology, 2017–2031
9.3.1. Liquid Phase
9.3.2. Solid Phase
9.3.3. Hybrid Phase
9.4. Market Attractiveness Analysis, by Technology

10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Type of Molecule, 2017–2031
10.3.1. Vasopressin
10.3.2. Somatostatin
10.3.3. Calcitonin
10.3.4. Natriuretic
10.4. Market Attractiveness Analysis, by Type of Molecule

11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by API Peptide Type ,2017–2031
11.3.1. In-house
11.3.2. CMO
11.4. Market Attractiveness Analysis, by API Peptide Type

12. Global Peptide Therapeutics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region

13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application,2017–2031
13.2.1. Cancer
13.2.2. Metabolic
13.2.3. CVD
13.2.4. Respiratory
13.2.5. GIT
13.2.6. Anti-infective
13.2.7. Dermatology
13.2.8. CNS
13.2.9. Renal
13.3. Market Value Forecast, by End-user,2017–2031
13.3.1. Parenteral
13.3.2. Oral
13.4. Market Value Forecast, by Type, 2017–2031
13.4.1. Innovative
13.4.2. Generic
13.5. Market Value Forecast, by Technology, 2017–2031
13.5.1. Liquid Phase
13.5.2. Solid Phase
13.5.3. Hybrid Phase
13.6. Market Value Forecast, by Type of Molecule, 2017–2031
13.6.1. Vasopressin
13.6.2. Somatostatin
13.6.3. Calcitonin
13.6.4. Natriuretic
13.7. Market Value Forecast, by API Peptide Type, 2017–2031
13.7.1. In-house
13.7.2. CMO
13.8. Market Value Forecast, by Country, 2017–2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Application
13.9.2. By Route of Administration
13.9.3. By Type
13.9.4. By Technology
13.9.5. By Type of Molecule
13.9.6. By API Peptide Type
13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Application, 2017–2031
14.2.1. Cancer
14.2.2. Metabolic
14.2.3. CVD
14.2.4. Respiratory
14.2.5. GIT
14.2.6. Anti-infective
14.2.7. Dermatology
14.2.8. CNS
14.2.9. Renal
14.3. Market Value Forecast, by End-user, 2017–2031
14.3.1. Parenteral
14.3.2. Oral
14.4. Market Value Forecast, by Type, 2017–2031
14.4.1. Innovative
14.4.2. Generic
14.5. Market Value Forecast, by Technology, 2017–2031
14.5.1. Liquid Phase
14.5.2. Solid Phase
14.5.3. Hybrid Phase
14.6. Market Value Forecast, by Type of Molecule, 2017–2031
14.6.1. Vasopressin
14.6.2. Somatostatin
14.6.3. Calcitonin
14.6.4. Natriuretic
14.7. Market Value Forecast, by API Peptide Type, 2017–2031
14.7.1. In-house
14.7.2. CMO
14.8. Market Value Forecast, by Country/Sub-region, 2017–2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Application
14.9.2. By Route of Administration
14.9.3. By Type
14.9.4. By Technology
14.9.5. By Type of Molecule
14.9.6. By API Peptide Type
14.9.7. By Country/Sub-region
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Application, 2017–2031
15.2.1. Cancer
15.2.2. Metabolic
15.2.3. CVD
15.2.4. Respiratory
15.2.5. GIT
15.2.6. Anti-infective
15.2.7. Dermatology
15.2.8. CNS
15.2.9. Renal
15.3. Market Value Forecast, by End-user, 2017–2031
15.3.1. Parenteral
15.3.2. Oral
15.4. Market Value Forecast, by Type, 2017–2031
15.4.1. Innovative
15.4.2. Generic
15.5. Market Value Forecast, by Technology, 2017–2031
15.5.1. Liquid Phase
15.5.2. Solid Phase
15.5.3. Hybrid Phase
15.6. Market Value Forecast, by Type of Molecule, 2017–2031
15.6.1. Vasopressin
15.6.2. Somatostatin
15.6.3. Calcitonin
15.6.4. Natriuretic
15.7. Market Value Forecast, by API Peptide Type, 2017–2031
15.7.1. In-house
15.7.2. CMO
15.8. Market Value Forecast, by Country/Sub-region, 2017–2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Application
15.9.2. By Route of Administration
15.9.3. By Type
15.9.4. By Technology
15.9.5. By Type of Molecule
15.9.6. By API Peptide Type
15.9.7. By Country/Sub-region
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Application, 2017–2031
16.2.1. Cancer
16.2.2. Metabolic
16.2.3. CVD
16.2.4. Respiratory
16.2.5. GIT
16.2.6. Anti-infective
16.2.7. Dermatology
16.2.8. CNS
16.2.9. Renal
16.3. Market Value Forecast, by End-user, 2017–2031
16.3.1. Parenteral
16.3.2. Oral
16.4. Market Value Forecast, by Type, 2017–2031
16.4.1. Innovative
16.4.2. Generic
16.5. Market Value Forecast, by Technology,2017–2031
16.5.1. Liquid Phase
16.5.2. Solid Phase
16.5.3. Hybrid Phase
16.6. Market Value Forecast, by Type of Molecule, 2017–2031
16.6.1. Vasopressin
16.6.2. Somatostatin
16.6.3. Calcitonin
16.6.4. Natriuretic
16.7. Market Value Forecast, by API Peptide Type, 2017–2031
16.7.1. In-house
16.7.2. CMO
16.8. Market Value Forecast, by Country/Sub-region, 2017–2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Application
16.9.2. By Route of Administration
16.9.3. By Type
16.9.4. By Technology
16.9.5. By Type of Molecule
16.9.6. By API Peptide Type
16.9.7. By Country/Sub-region

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Application, 2017–2031
17.2.1. Cancer
17.2.2. Metabolic
17.2.3. CVD
17.2.4. Respiratory
17.2.5. GIT
17.2.6. Anti-infective
17.2.7. Dermatology
17.2.8. CNS
17.2.9. Renal
17.3. Market Value Forecast, by End-user, 2017–2031
17.3.1. Parenteral
17.3.2. Oral
17.4. Market Value Forecast, by Type, 2017–2031
17.4.1. Innovative
17.4.2. Generic
17.5. Market Value Forecast, by Technology, 2017–2031
17.5.1. Liquid Phase
17.5.2. Solid Phase
17.5.3. Hybrid Phase
17.6. Market Value Forecast, by Type of Molecule, 2017–2031
17.6.1. Vasopressin
17.6.2. Somatostatin
17.6.3. Calcitonin
17.6.4. Natriuretic
17.7. Market Value Forecast, by API Peptide Type, 2017–2031
17.7.1. In-house
17.7.2. CMO
17.8. Market Value Forecast, by Country/Sub-region, 2017–2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Application
17.9.2. By Route of Administration
17.9.3. By Type
17.9.4. By Technology
17.9.5. By Type of Molecule
17.9.6. By API Peptide Type
17.9.7. By Country/Sub-region

18. Competition Landscape
18.1. Market Player – Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2021
18.3. Company Profiles
18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Strategic Overview
18.3.2. Bachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Strategic Overview
18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Strategic Overview
18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Strategic Overview
18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Strategic Overview
18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Strategic Overview
18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Strategic Overview
18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Strategic Overview
18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Strategic Overview
18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2021 and 2031

Figure 02: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 03: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 04: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 05: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 06: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 07: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 08: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 09: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 12: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2022–2031

Figure 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2021–2031

Figure 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2021–2031

Figure 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2021–2031

Figure 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 18: Global Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

Figure 19: Global Innovative Peptide Therapeutics Market Size (US$ Mn), 2021–2031

Figure 20: Global Generic Peptide Therapeutics Market Size (US$ Mn), 2021–2031

Figure 21: Global Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 21: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2021 and 2031

Figure 22: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 23: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 24: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 25: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 26: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2021 and 2031

Figure 27: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 28: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 29: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 30: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 31: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 32: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 33: Global Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule, 2022–2031

Figure 34: Global API Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

Figure 35: Global In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 36: Global CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 37: Global API Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 38: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 39: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 40: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 41: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 42: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 43: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 44: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 45: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 46: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 50: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 51: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 52: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 53: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 54: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 55: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 56: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 60: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 61: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 62: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 63: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 64: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 68: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 69: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 70: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 71: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 75: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 76: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 77: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 78: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 82: Peptide Therapeutics Market Share Analysis, by Company, 2021

List of Tables

List of Table

Table 01: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 02: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2021–2031

Table 03: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 04: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 05: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 06: Global API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 07: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021–2031

Table 08: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 09: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031